Close
28/05/2015
Synchrotron light applications for the pharmaceutical industry
More than forty people from the pharmaceutical sector attended the workshop organised by the ALBA Synchrotron on May 7.

Researchers from the MSPD, CLAESS, XALOC, NCD and MISTRAL ALBA beam lines have shown the available state-of-the-art techniques and the advantages that they offer in this field: fast data acquisition and shorter experiments, cost savings and, in the case of X-ray microscopy, suppression of ethical conflicts because this technique can be a previous step before clinical essays with animals and persons.

The companies Enantia and Almirall, which have already collaborated with the ALBA Synchrotron, have commented their own experiences at the facility. Enantia, specialised in research solutions for other companies, has detailed different examples. For Almirall, the analysis of polymorphic compounds – performed at ALBA – has increased its quality control, verifying and quantifying purity grades.

News based on the press release issued by the ALBA synchrotron.

Image: ALBA synchrotron. Structure of a herpesvirus nuclease-antiviral complex. Data collected at the Xaloc beam line (Bongarzone, S., Nadal, M. & Coll, M., IBMB)

More news

14/12/2018 The Open Innovation Forum matches business challenges to academic solutions 07/12/2018 2017 BioCat report: The best of the Bioregion of Catalonia 30/11/2018 Barcelona Synchrotron Park’s Commitment to Sustainable Growth 23/11/2018 Astronomers led by IEEC reveal a cold super-Earth around Barnard’s star 16/11/2018 CRAG’s Researchers discover how to generate plants with enhanced drought resistance 08/11/2018 The Barcelona manifesto: for a city-led science and technology diplomacy
6 7 8 9 10 11 12 13 14 15 16